Genetic Disorders
Aro Biotherapeutics enrols first subject in Phase I Pompe disease trial
Aro Biotherapeutics has enrolled the first subject in its Phase I clinical trial of ABX1100 to treat Pompe disease. Launched…
Mirum Pharmaceuticals reports positive data from Chenodal trial
US-based biopharmaceutical company Mirum Pharmaceuticals has reported positive findings from the Phase III RESTORE clinical trial of Chenodal (chenodiol) tablets to treat…
Pipeline Moves: Advancement prospects plunge for myelodysplastic syndrome drug after trial termination
This week on Pipeline Moves, we kickoff by looking at the terminations of a Phase II trial in myelodysplastic syndrome…
Pipeline Moves: Advancement prospects plunge for Parkinson’s drug after trial termination
This week on Pipeline Moves, we kick off by looking at the termination of a Phase III trial in parkinson’s…
Pipeline Moves: Advancement prospects plunge for Bristol-Myers’ oncology drug after trial termination
This week on Pipeline Moves, we kick off by looking at the terminations of Phase II trials in metastatic hepatocellular…
Kintor concludes enrolment in androgenetic alopecia therapy trial
Kintor Pharmaceutical has concluded the enrolment of 180 subjects in the Phase II clinical trial of GT20029 to treat male…
FDA lifts clinical hold on Fulcrum’s sickle cell disease candidate
The US Food and Drug Administration (FDA) has given the green light to Fulcrum Therapeutics to continue a study investigating…
Pipeline Moves: Advancement prospects halt for refractory acute myeloid leukaemia therapy after trial suspension
This week on Pipeline Moves, we kickoff by looking at the the suspension of a Phase Ib trial in refractory…
Eloxx reports all patients in Phase II Alport syndrome trial have improved
Eloxx Pharmaceuticals has reported that all patients with Alport syndrome treated with drug candidate ELX-02 have shown improvement. The Massachusetts-based…
AceLink opens first site for study of Fabry disease therapy
AceLink Therapeutics has opened the first clinical trial site in China for conducting its Phase II study of AL01211 for…
